|
1
|
Wong ML and Licinio J: Research and
treatment approaches to depression. Nat Rev Neurosci. 2:343–351.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Melfi CA, Chawla AJ, Croghan TW, Hanna MP,
Kennedy S and Sredl K: The effects of adherence to antidepressant
treatment guidelines on relapse and recurrence of depression. Arch
Gen Psychiatry. 55:1128–1132. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gumnick JF and Nemeroff CB: Problems with
currently available antidepressants. J Clin Psychiatry. 61:5–15.
2000.PubMed/NCBI
|
|
4
|
Tian JW, Jiang WL, Zhong Y, Meng Q, Gai Y,
Zhu HB, Hou J, Xing Y and Li YX: Preclinical pharmacology of TP1, a
novel potent triple reuptake inhibitor with antidepressant
properties. Neuroscience. 196:124–130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Otton SV, Ball SE, Cheung SW, Inaba T,
Rudolph RL and Sellers EM: Venlafaxine oxidation in vitro is
catalysed by CYP2D6. Br J Clin Pharmacol. 41:149–156. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klamerus KJ, Maloney K, Rudolph RL,
Sisenwine SF, Jusko WJ and Chiang ST: Introduction of a composite
parameter to the pharmacokinetics of venlafaxine and its active
O-desmethyl metabolite. J Clin Pharmacol. 32:716–724. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schweizer E, Thielen RJ and Frazer A:
Venlafaxine: A novel antidepressant compound. Expert Opin Investig
Drugs. 6:65–78. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perry R and Cassagnol M: Desvenlafaxine: A
new serotonin-norepinephrine reuptake inhibitor for the treatment
of adults with major depressive disorder. Clin Ther. 31:1374–1404.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rudorfer MV and Potter WZ: The role of
metabolites of antidepressants in the treatment of depression. CNS
Drugs. 7:273–312. 1997. View Article : Google Scholar
|
|
10
|
Ereshefsky L and Dugan D: Review of the
pharmacokinetics, pharmacogenetics, and drug interaction potential
of antidepressants: Focus on venlafaxine. Depress Anxiety. 12(Suppl
1): S30–S44. 2000. View Article : Google Scholar
|
|
11
|
Nichols AI, Focht K, Jiang Q, Preskorn SH
and Kane CP: Pharmacokinetics of venlafaxine extended release 75 mg
and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor
metabolizers: A randomized, open-label, two-period, parallel-group,
crossover study. Clin Drug Investig. 31:155–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nichols AI, Abell M, Chen Y, Behrle JA,
Frick G and Paul J: Effects of desvenlafaxine on the
pharmacokinetics of desipramine in healthy adults. Int Clin
Psychopharmacol. 28:99–105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reddy S, Kane C, Pitrosky B, Musgnung J,
Ninan PT and Guico-Pabia CJ: Clinical utility of desvenlafaxine 50
mg/d for treating MDD: A review of two randomized
placebo-controlled trials for the practicing physician. Curr Med
Res Opin. 26:139–150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sproule BA, Hazra M and Pollock BG:
Desvenlafaxine succinate for major depressive disorder. Drugs Today
(Barc). 44:475–487. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nichols AI, Tourian KA, Tse SY and Paul J:
Desvenlafaxine for major depressive disorder: Incremental clinical
benefits from a second-generation serotonin-norepinephrine reuptake
inhibitor. Expert Opin Drug Metab Toxicol. 6:1565–1574. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mizuno N, Niwa T, Yotsumoto Y and Sugiyama
Y: Impact of drug transporter studies on drug discovery and
development. Pharmacol Rev. 55:425–461. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baudy RB, Butera JA, Abou-Gharbia MA, Chen
H, Harrison B, Jain U, Magolda R, Sze JY, Brandt MR, Cummons TA, et
al: Prodrugs of perzinfotel with improved oral bioavailability. J
Med Chem. 52:771–778. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie Q, Wang X, Jiang Z and Qiu Z: Design,
synthesis, and bioavailability evaluation of coumarin-based prodrug
of meptazinol. Bioorg Med Chem Lett. 15:4953–4956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kahns AH, Møss J and Bundgaard H: Improved
oral bioavailability of salicylamide in rabbits by a
1,3-benzoxazine-2,4-dione prodrug. Int J Pharm. 78:199–202. 1992.
View Article : Google Scholar
|
|
20
|
Horn AS, Kelly P, Westerink BH and
Dijkstra DA: A prodrug of ADTN: Selectivity of dopaminergic action
and brain levels of ADTN. Eur J Pharmacol. 60:95–99. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ecobichon D: Relative amounts of hepatic
and renal carboxylesterase in mammalian species. Res Commun Chem
Pathol Pharmacol. 3:629–636. 1972.PubMed/NCBI
|
|
22
|
Cook CS, Karabatsos PJ, Schoenhard Gl and
Karim A: Species dependent esterase activities for hydrolysis of an
anti-HIV prodrug glycovir and bioavailability of active SC-48334.
Pharm Res. 12:1158–64. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Yang Y, Zhao S, Yang Z, Yang H,
Fawcett JP, Li Y, Gu J and Sun T: Phenolic esters of
O-desmethylvenlafaxine with improved oral bioavailability and brain
uptake. Molecules. 18:14920–14934. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liederer BM and Borchardt RT: Enzymes
involved in the bioconversion of ester-based prodrugs. J Pharm Sci.
95:1177–1195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beaumont K, Webster R, Gardner I and Dack
K: Design of ester prodrugs to enhance oral absorption of poorly
permeable compounds: challenges to the discovery scientist. Curr
Drug Metab. 4:461–485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ettmayer P, Amidon GL, Clement B and Testa
B: Lessons learned from marketed and investigational prodrugs. J
Med Chem. 47:2393–2404. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Testa B: Prodrug research: Futile or
fertile? Biochem Pharmacol. 68:2097–2106. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stella VJ and Nti-Addae KW: Prodrug
strategies to overcome poor water solubility. Adv Drug Deliv Rev.
59:677–694. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rautio J, Kumpulainen H, Heimbach T,
Oliyai R, Oh D, Järvinen T and Savolainen J: Prodrugs: Design and
clinical applications. Nat Rev Drug Discov. 7:255–270. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Laizure SC1, Herring V, Hu Z, Witbrodt K
and Parker RB: The role of human carboxylesterases in drug
metabolism: Have we overlooked their importance? Pharmacotherapy.
33:210–222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pindel EV, Kedishvili NY, Abraham TL,
Brzezinski MR, Zhang J, Dean RA and Bosron WF: Purification and
cloning of a broad substrate specificity human liver
carboxylesterase that catalyzes the hydrolysis of cocaine and
heroin. J Biol Chem. 272:14769–14775. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schewer H, Langmann T, Daig R, Becker A,
Aslandis C and Schmitz G: Molecular cloning and characterization of
a novel putative carboxylesterase, present in human intestine and
liver. Biochem Biophys Res Commun. 233:117–120. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Holmes RS, Glenn JP, Vandeberg JL and Cox
LA: Baboon carboxylesterases 1 and 2: Sequences, structures and
phylogenetics relationships with human and other primate
carboxylesterases. J Med Primatol. 38:27–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Song X and Siahaan TJ: Synthesis and
stability study of a modified phenylpropionic acid linker-based
esterase-sensitive prodrug. Bioorg Med Chem Lett. 12:3439–3442.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sakaguchi K, Nagayama M, Masaoka T,
Nishimura A, Kageyama K, Shirai M and Akahori F: Effects of
fenthion, isoxathion, dichlorvos and propaphos on the serum
cholinesterase isoenzyme patterns of dogs. Vet Hum Toxicol. 39:1–5.
1997.PubMed/NCBI
|
|
36
|
Taketani M, Shii M, Ohura K, Ninomiya S
and Imai T: Carboxylesterase in the liver and small intestine of
experimental animals and human. Life Sci. 81:924–932. 2007.
View Article : Google Scholar : PubMed/NCBI
|
